<code id='D6DBC25DE6'></code><style id='D6DBC25DE6'></style>
    • <acronym id='D6DBC25DE6'></acronym>
      <center id='D6DBC25DE6'><center id='D6DBC25DE6'><tfoot id='D6DBC25DE6'></tfoot></center><abbr id='D6DBC25DE6'><dir id='D6DBC25DE6'><tfoot id='D6DBC25DE6'></tfoot><noframes id='D6DBC25DE6'>

    • <optgroup id='D6DBC25DE6'><strike id='D6DBC25DE6'><sup id='D6DBC25DE6'></sup></strike><code id='D6DBC25DE6'></code></optgroup>
        1. <b id='D6DBC25DE6'><label id='D6DBC25DE6'><select id='D6DBC25DE6'><dt id='D6DBC25DE6'><span id='D6DBC25DE6'></span></dt></select></label></b><u id='D6DBC25DE6'></u>
          <i id='D6DBC25DE6'><strike id='D6DBC25DE6'><tt id='D6DBC25DE6'><pre id='D6DBC25DE6'></pre></tt></strike></i>

          Home / hotspot / knowledge

          knowledge


          knowledge

          author:explore    Page View:47
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In